These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35238282)

  • 1. Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals.
    Duong A; Thirion DJG; Williamson D; Simard C; Marsot A
    J Chemother; 2022 Sep; 34(5):341-344. PubMed ID: 35238282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.
    Grucz TM; Kruer RM; Bernice F; Lipsett PA; Dorman T; Sugrue D; Jarrell AS
    Surg Infect (Larchmt); 2020 Dec; 21(10):859-864. PubMed ID: 32302517
    [No Abstract]   [Full Text] [Related]  

  • 3. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
    Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
    Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity.
    De Broe ME; Giuliano RA; Verpooten GA
    Am J Med; 1986 Jun; 80(6B):115-8. PubMed ID: 3728523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients.
    Mareville J; Gay J; Cliquennois E; Herbaux C; Pasquier F; Allorge D; Blondiaux N; Berthon C; Alfandari S
    Scand J Infect Dis; 2012 May; 44(5):398-401. PubMed ID: 22235869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring.
    Agence française de sécurité sanitaire des produits de santé
    Med Mal Infect; 2012 Jul; 42(7):301-8. PubMed ID: 22770656
    [No Abstract]   [Full Text] [Related]  

  • 9. External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study.
    Hartman SJF; Orriëns LB; Zwaag SM; Poel T; de Hoop M; de Wildt SN
    Paediatr Drugs; 2020 Aug; 22(4):433-444. PubMed ID: 32507958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
    Duong A; Simard C; Wang YL; Williamson D; Marsot A
    Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33946905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin.
    Brewer NS
    Mayo Clin Proc; 1977 Nov; 52(11):675-9. PubMed ID: 336988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside usage and monitoring in a Saudi Arabian teaching hospital: a ten-year laboratory audit.
    Adjepon-Yamoah KK; Al-Homrany M; Bahar Y; Ahmed ME
    J Clin Pharm Ther; 2000 Aug; 25(4):303-7. PubMed ID: 10971782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable?
    Duong A; Simard C; Williamson D; Marsot A
    Ther Drug Monit; 2023 Oct; 45(5):616-622. PubMed ID: 36917735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.
    Cross AS; Opal S; Kopecko DJ
    Arch Intern Med; 1983 Nov; 143(11):2075-80. PubMed ID: 6639227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aminoglycosides. Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, sisomicin.
    Edson RS; Keys TF
    Mayo Clin Proc; 1983 Feb; 58(2):99-102. PubMed ID: 6823164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aminoglycoside-use restrictions on drug cost.
    DeTorres OH; White RE
    Am J Hosp Pharm; 1984 Jun; 41(6):1137-9. PubMed ID: 6430070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic monitoring of amikacin and gentamicin in routine clinical practice].
    Kacířová I; Grundmann M
    Vnitr Lek; 2015 Jan; 61(1):33-41. PubMed ID: 25693614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.